162 related articles for article (PubMed ID: 7718903)
1. Evaluation of CD38 as target for immunotherapy in multiple myeloma.
Vooijs WC; Schuurman HJ; Bast EJ; de Gast GC
Blood; 1995 Apr; 85(8):2282-4. PubMed ID: 7718903
[No Abstract] [Full Text] [Related]
2. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
Goldmacher VS; Bourret LA; Levine BA; Rasmussen RA; Pourshadi M; Lambert JM; Anderson KC
Blood; 1994 Nov; 84(9):3017-25. PubMed ID: 7524764
[TBL] [Abstract][Full Text] [Related]
3. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
[TBL] [Abstract][Full Text] [Related]
4. Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells.
Randall TD; Lund FE; Howard MC; Weissman IL
Blood; 1996 May; 87(10):4057-67. PubMed ID: 8639761
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.
Hata H; Matsuzaki H; Matsuno F; Sonoki T; Takemoto S; Kuribayashi N; Nagasaki A; Takatsuki K
Clin Exp Immunol; 1994 May; 96(2):370-5. PubMed ID: 8187346
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
7. CD38 in hematopoietic malignancies.
Konopleva M; Rissling I; Andreeff M
Chem Immunol; 2000; 75():189-206. PubMed ID: 10851785
[No Abstract] [Full Text] [Related]
8. Functional differences between CD38- and DR- subfractions of CD34+ bone marrow cells.
Rusten LS; Jacobsen SE; Kaalhus O; Veiby OP; Funderud S; Smeland EB
Blood; 1994 Sep; 84(5):1473-81. PubMed ID: 7520773
[TBL] [Abstract][Full Text] [Related]
9. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
Kimlinger T; Witzig TE
Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
[TBL] [Abstract][Full Text] [Related]
10. Leu-19 in myeloma--a new role for an old antibody.
Wetter O; Brandhorst D; Reiter W
Eur J Cancer; 1990 Apr; 26(4):541. PubMed ID: 1694090
[No Abstract] [Full Text] [Related]
11. Multiple myeloma: expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation.
Petersen AJ; Brown RD; Pope BB; Jamieson GP; Paterson AR; Gibson J; Wiley JS; Joshua DE
Leuk Lymphoma; 1994 May; 13(5-6):491-9. PubMed ID: 8069194
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies to human tumor antigens.
Wright GL; Cox AD
Curr Top Pathol; 1987; 77():1-18. PubMed ID: 3322690
[No Abstract] [Full Text] [Related]
13. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia.
Turhan AG; Lemoine FM; Debert C; Bonnet ML; Baillou C; Picard F; Macintyre EA; Varet B
Blood; 1995 Apr; 85(8):2154-61. PubMed ID: 7536493
[TBL] [Abstract][Full Text] [Related]
14. Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin.
Petzer AL; Zandstra PW; Piret JM; Eaves CJ
J Exp Med; 1996 Jun; 183(6):2551-8. PubMed ID: 8676076
[TBL] [Abstract][Full Text] [Related]
15. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells.
Yi Q; Dabadghao S; Osterborg A; Bergenbrant S; Holm G
Blood; 1997 Sep; 90(5):1960-7. PubMed ID: 9292530
[TBL] [Abstract][Full Text] [Related]
16. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.
Goulet AC; Goldmacher VS; Lambert JM; Baron C; Roy DC; Kouassi E
Blood; 1997 Sep; 90(6):2364-75. PubMed ID: 9310487
[TBL] [Abstract][Full Text] [Related]
17. Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells.
Olweus J; Lund-Johansen F; Terstappen LW
Immunomethods; 1994 Dec; 5(3):179-88. PubMed ID: 7540098
[TBL] [Abstract][Full Text] [Related]
18. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells.
Gazitt Y
Leukemia; 1999 Nov; 13(11):1817-24. PubMed ID: 10557057
[TBL] [Abstract][Full Text] [Related]
19. Changes in the growth properties of CD34+, CD38- bone marrow progenitors during human fetal development.
Waller EK; Huang S; Terstappen L
Blood; 1995 Jul; 86(2):710-8. PubMed ID: 7541673
[TBL] [Abstract][Full Text] [Related]
20. Release from quiescence of CD34+ CD38- human umbilical cord blood cells reveals their potentiality to engraft adults.
Cardoso AA; Li ML; Batard P; Hatzfeld A; Brown EL; Levesque JP; Sookdeo H; Panterne B; Sansilvestri P; Clark SC
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8707-11. PubMed ID: 7690969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
